What is HC Wainwright’s Estimate for CTXR FY2024 Earnings?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Equities research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Citius Pharmaceuticals in a report issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.26) per share for the year, down from their prior estimate of ($0.21). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.18) EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01).

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $0.33 on Thursday. Citius Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $1.07. The firm has a market capitalization of $59.35 million, a price-to-earnings ratio of -1.61 and a beta of 1.66. The company’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.60.

Hedge Funds Weigh In On Citius Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its stake in Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after buying an additional 32,686 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Citius Pharmaceuticals during the second quarter worth about $29,000. Arkadios Wealth Advisors raised its position in shares of Citius Pharmaceuticals by 33.3% during the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after purchasing an additional 50,000 shares during the period. Wealth Advisory Solutions LLC lifted its holdings in shares of Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Citius Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after purchasing an additional 104,889 shares during the period. 16.88% of the stock is owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.